
Alzheimer's may be delayed through lifestyle changes, new studies show
Richardson, now 51, remembers crying when she got the news. 'I was terrified,' she said. 'It's a horrible, horrible disease with no cure.'
So Richardson, a business owner in Richmond, Virginia, decided to make whatever changes she could to reduce her risk of the disease. 'I do what I can to get enough sleep. I keep active. I try to eat well and maintain a healthy weight, and I'm always working my brain to learn new things,' she said.
Two new studies being presented at the Alzheimer's Association meeting Monday in Toronto may give some hope to Richardson and others who carry a genetic risk for the disease. Both new studies build on previous evidence that diet, certain brain training exercises and physical activity can delay the loss of memory and slow the decline of other cognitive abilities.
One study looked at the impact of walking on 2,985 Black and white older adults who were tested for APOE status and were followed for 10 years. Each year, the participants were questioned about the amount of walking they did, and at multiple points during the follow-up period, their cognitive status was evaluated with standardized exams.
Overall, participants with the APOE4 gene mutation showed steeper declines in cognition compared with those with other forms of the gene that don't raise the risk of Alzheimer's. While walking appeared to have a protective effect on all the participants, it was strongest among those with APOE4.
The risk of developing Alzheimer's among those with two copies of APOE4 is 12 times that of women with none and four times that of men with none, said the study's senior author, Cindy Barha, an assistant professor of neuroscience at the University of Calgary and Canada Research chair in neuroscience, brain health and exercise.
That changed significantly if people walked. Overall, women benefited more.
A 10% higher amount of self-reported walking was associated with a 4.7% increase in complex thinking performance over time in women and a 2.6% increase in men.
Among APOE4 carriers, men appeared to benefit more. A 10% higher amount of self-reported walking was associated with an 8.5% increase in global cognitive performance over time in women and a 12% increase in men. That was a surprise to the researchers, who expected that women would continue to benefit more.
Walking seems to keep brains healthier by pumping up levels of brain-derived neurotrophic factor (BDNF), a protein that's known to support the health of brain cells, Barha said. Other proteins in the brain may be involved, as well.
'BDNF is like fertilizer for your brain that is naturally produced, especially when you are being physically active, such as when you are walking,' Barha said. 'It helps brain cells survive, grow and form stronger connections; this supports memory, learning and mood, especially in the hippocampus, which is the brain's memory center.'
A limitation of the study is that it didn't track how fast or how frequently the participants walked.
Dementia risk modified through lifestyle
The second international study, led by researchers in Finland, found that a combination of lifestyle modifications could also benefit people with the APOE4 variation more than those with other mutations.
The study included 2,469 participants from France, Japan and Finland who were randomly assigned to receive multi-focus lifestyle interventions or not. Among the participants were 709 APOE4 carriers.
Included in the lifestyle modifications were:
Cognitive training, either computer-based or with paper and pencil.
Physical activity, including group-based physical group exercise sessions lasting 90 minutes and an exercise program supervised by physiotherapists at the gym.
Dietary counseling.
A preliminary analysis revealed that the benefit of the intervention was greater among the APOE4 carriers.
Study co-author Jenni Lehtisalo, a research fellow at the Finnish Institute for Health and Welfare, said the main takeaway is that the risk for dementia, even in people with genetic predisposition, can be modified through lifestyle.
There was about a fourfold greater benefit in those who were positive for APOE4, said Lehtisalo, who is also a visiting researcher at the University of Eastern Finland.
The hope is that future research will reveal whether there is a specific window of time during which the modifications are more effective, she said.
Dr. Cynthia Boyd, a professor of medicine and director of the division of geriatric medicine and gerontology at Johns Hopkins Medicine, said the studies show 'there is something concrete we can all do to decrease the risk of cognitive decline.'
'Walking and other lifestyle modifications can be protective for the brain,' said Boyd, who wasn't involved in the new research.
Adam Brickman, a professor of neuropsychology at Columbia University Vagelos College of Physicians and Surgeons, said that to optimize brain and cognitive health, it's a good idea for everyone, regardless of genetic risk, to engage in physical activity, maintain a good diet and monitor other risk factors linked to dementia.
'Sometimes initiating new healthy behaviors is difficult for people," Brickman said. "Knowledge of being at increased risk for Alzheimer's disease by virtue of having an APOE4 allele may help inspire or motivate lifestyle changes to mitigate that risk.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Boston Globe
23 minutes ago
- Boston Globe
City announces $5 million in grants to address health inequalities in Dorchester, Mattapan, and Roxbury
'It means making sure that a mom can afford to feed her kids, access the doctor for those kids, make it to work on time and pay her rent without feeling like she's one [medical] visit away from being underwater,' Wu said, speaking at a press conference at the Great Hall at the Codman Square Health Center in Dorchester. Advertisement The grant money, provided by the Atrius Health Equity Foundation, will also be used to address disparities such as the gap in life expectancy among residents of the three neighborhoods, officials said. 'If you zoom out and look at our city as a whole, we have concerning disparities by race. Life expectancy amongst Black people as a whole is seven years lower than other Bostonians,' Ojikutu said. ' We believe that how long you live should not depend upon your race or ethnicity or your zip code.' And, when it comes to health in Boston, two miles makes a big difference. Some residents in Back Bay have a Advertisement The 23-year gap is just one of several issues identified by the commission facing residents, research shows. The main causes for premature death in Boston are cardiometabolic diseases, cancer, and unintentional drug overdoses, Wu noted that the city was prioritizing spending to address health, as President Trump's ' 'We are doubling down in the face of a federal administration that is clawing back access to critical life-changing resources, that's canceling research that will save lives, and who passed a bill that is certainly not beautiful,' Wu said. Each coalition is made up of three nonprofits that will team up to address critical issues underlying the disparities in health care. For example, the Boys & Girls Clubs of Boston, Link Health, and the Harvard Street Neighborhood Health Center will collaborate on a project where Boys and Girls Club alumni will be trained to meet Dorchester residents at health centers to help them access financial assistance benefits. 'Every single night in my emergency room, I see patients living on less than $20,000 a year making decisions between medications and food,' said Dr. Alister Martin of Link Health. 'Young folks from Boys and Girls Club ... will meet people where they're at, in the waiting rooms, and enroll them in these cash assistance programs.' Advertisement Wu said that the city wanted to give out the funding to coalitions so that the work of different nonprofits could be better coordinated. 'I think the way that a lot of cities would have done this, even with the same amount of resources ... is to put 15 different grants out the door and hope that it adds up,' Wu said. 'But this is about launching new and needed coalitions.' The coalitions each received $200,000 to fund the first year of their projects. They will each be awarded the remaining $1,050,000 over the next two years. For Christine Sinclair, a registered dietitian who works at Stop and Shop in Grove Hall, the collaboration among the Boys & Girls Club, the Harvard Street Neighborhood Health Center, and Link Health means that more patients will get access to healthy food. Sinclair currently runs a program funded by the city's public health commission where she provides education to roughly 35 patients with diabetes and helps them make healthier choices while buying groceries. 'We track their A1C levels and we've definitely seen progress,' Sinclair said, referring to blood sugar levels. In other projects, Upham's Community Care will deploy mobile health vans in the community, the Dorchester Food Co-op will give residents access to healthy food, and the Jamaica Plain Neighborhood Development Corporation will provide financial literacy courses. 'We'll be able to meet community members where they live, where they go to school, where they congregate and try to bring the services to them,' said Jagdeep 'Jay' Trivedi, chief executive officer of Upham's Corner Health Center. Advertisement Immigrant Family Services Institute, the True Care Alliance Center, and the Massachusetts Association of Haitian Parents will collaborate to provide job training for 50 community health workers and for 500 immigrants hoping to enter the health care, biotechnology, early childhood education, and hospitality industries. 'We will be providing access, because in Mattapan this is something that we do not have,' said Dr. Geralde Gabeau, founder and executive director of the institute. 'We're going to provide English classes, computer classes, and ... help our young people think of jobs of the future.' The Community Builders, Codman Square Neighborhood Development Corporation, and Talbot Norfolk Triangle Neighbors United will team up to help eligible Dorchester residents build credit and find stable housing. The money will also be used to expand The Community Builders' food pantry. Angela Mathew can be reached at


Indianapolis Star
2 hours ago
- Indianapolis Star
GEN and Sulfateq BV Announce Positive Phase 1 Trial Data on Investigational Drug SUL-238 for Alzheimer's and Other Neurodegenerative Diseases
Phase 1 results demonstrate that SUL-238, a first-in-class, orally administered, mitochondria-directed drug candidate, is safe and well-tolerated in healthy elderly volunteers, showing a favourable pharmacokinetic profile and high brain penetration. These findings support the advancement of SUL-238 into further clinical development for Alzheimer's and other neurodegenerative diseases. ANKARA, TR / ACCESS Newswire / July 28, 2025 / GEN Pharmaceuticals ( Türkiye's leading specialty pharmaceutical company, announced positive results from its Phase 1 clinical trial evaluating the safety, tolerability, and pharmacokinetics (PK) of first-in-class and novel orally administered mitochondria-directed drug candidate SUL-238 in healthy elderly volunteers. The findings were presented at the Alzheimer's Association International Conference 2025 (AAIC ®) in Toronto. This single oral ascending dose (SAD) Phase 1, first-in-human, randomized, double-blind, placebo-controlled study was conducted in three parts, involving a total of 53 healthy elderly adults. Part 1 included 6 cohorts (50, 100, 250, 500, 1000, and 2000 mg orally, n=23). In Part 2, the PK of a single 1000 mg oral dose was investigated in 10 healthy elderly adults. In Part 2B, the food effect was assessed using a randomized, single oral 2000 mg dose, two-treatment, two-period, crossover design (n=20). The trial results showed that single oral doses of 50-2000 mg of SUL-238 were safe and well-tolerated, while demonstrating a favourable PK profile and high cerebrospinal fluid (CSF) penetration. These findings make SUL-238 a promising candidate for further clinical development in neurodegenerative diseases, including Alzheimer's disease. No adverse effects (AEs) limited dose escalation, AE rates were comparable between SUL-238 and placebo, and all AEs were mild or moderate. The mean terminal elimination half-life was 0.86-3.80 hours, and the time to maximum plasma concentration was 0.50-1.39 hours. Under fed conditions, maximum plasma concentration (C max) and area under the plasma concentration-time curve (AUC 0-∞) decreased by 50% and 60%, respectively. CSF-to-plasma percentages at 2 and 8 hours post-dose were 21.1% (±6.6%) and 74.2% (±46.0%). Abidin Gülmüş, Chairman of GEN, stated: 'We are very encouraged by these promising first-in-human results, marking an important step forward in our mission to address the underlying biology of Alzheimer's disease.' Nadir Ulu, MD, PhD, Vice President of R&D at GEN, added: 'With its excellent safety and PK profile in this Phase 1 trial, combined with robust preclinical data, SUL-238 represents a strong candidate for further clinical development to meet the critical unmet needs in neurodegenerative diseases, including Alzheimer's disease.' About SUL-238 SUL-238 is a novel, first-in-class, hibernation-derived small molecule that targets mitochondria, the cell's 'powerhouse.' It supports mitochondrial bioenergetics via complex I/IV activation and has improved mitochondrial function in rodent models of neurodegenerative, cardiovascular, and renal diseases, as well as aging. SUL-238 crosses the blood-brain barrier and has undergone extensive safety evaluation in preclinical and Phase 1 studies. GEN licenses SUL-238 from Sulfateq BV for neurodegenerative disease applications. About GEN: Founded in 1998, GEN is Türkiye's leading specialty pharmaceutical company, focused on developing innovative therapies across multiple therapeutic areas. GEN manufactures high-quality, competitive products at its GMP-certified facility and pursues original drug development through two dedicated R&D centers and investments. About Sulfateq: Sulfateq B.V. is an early-stage Dutch biotech company that fosters strategic collaborations with academic and industrial research centers to accelerate the development of innovative new medicines. It has developed a novel class of small molecules, the SUL-compounds, that maintain mitochondrial health. Contact Information Bulutay Güneş Sr. Head of Corporate Brand Ali Ketencioğlu Investor Relations Manager Kees van der Graaf Sulfateq CEO View the original press release on ACCESS Newswire The post GEN and Sulfateq BV Announce Positive Phase 1 Trial Data on Investigational Drug SUL-238 for Alzheimer's and Other Neurodegenerative Diseases appeared first on DA80 Hub.
Yahoo
4 hours ago
- Yahoo
Early results from major clinical trial show healthy lifestyle slows cognitive decline
Phyllis Jones wakes up every morning to work up a sweat in countries all over the world, 'and even sometimes on the moon,' she said, thanks to her favorite workout gadget, a virtual reality headset. Her focus on exercise is light-years away from where Jones, 66, of Aurora, Illinois, was just a few years ago. She had prediabetes, and her cholesterol and blood pressure levels were inching up. She was totally sedentary after falling into deep depression. 'I was in bed. I didn't care at all. I was just spiraling,' Jones said. She was probably also destined to lose her ability to think clearly. Jones' mother and grandmother died of vascular dementia, a condition that occurs when the body can't pump enough blood to the brain. Other family members had the disease, too. 'Watching two generations suffer made me determined to break the cycle for myself,' Jones said. 'I'm not that person anymore.' Four years ago, Jones joined a major clinical trial, called U.S. POINTER, that aimed to figure out how older adults at high risk for dementia can stay healthier longer. Half of the more than 2,000 participants were given advice on a healthy lifestyle, including diet and exercise. The other half was thrust into a structured, team-based program that gave participants goals to transform their lifestyles. The program included meeting with experts and other participants regularly, as well as brain exercises and aerobics classes. Participants were instructed to follow the MIND diet, which trades processed foods for whole grains, fruits, leafy greens and other vegetables. The researchers evaluated cognitive function by measuring memory, the ability to focus while juggling multiple tasks, and how quickly people interpreted and responded to information. After two years, both groups showed progress. But people in the structured group saw greater benefits. 'Our conservative estimate shows that, relative to the self-guided group, the structured group performed at a level comparable to adults who were one to two years younger in age,' said Laura Baker, lead researcher and a gerontology professor at Wake Forest University School of Medicine and Advocate Health in Winston-Salem, North Carolina. 'This is what's giving folks additional resilience against cognitive decline,' she said. Greater support and accountability in the structured group were key benefits. 'We're going to tell you what to do, but we're also going to help you get there, and we're going to work with you as a partner to meet you where you are,' Baker said during a news briefing about the findings Monday at the Alzheimer's Association International Conference in Toronto. The research, published simultaneously in the Journal of the American Medical Association, is the first large-scale randomized controlled trial to show that organized, sustainable lifestyle interventions can have a measurable impact on brain health. It's an important finding as the nation is on a path to double the number of people living with dementia by 2060. About 10% of Americans over age 65 have been diagnosed with dementia, according to the Centers for Disease Control and Prevention. Nearly 7 million people in the U.S. have Alzheimer's, the most common type of dementia. While some drugs may slow how quickly dementia develops, there is no cure. 'Some people are scared, thinking there's nothing you can do' to ward off dementia, said Dr. Richard Isaacson, a neurologist and researcher at the Institute for Neurodegenerative Diseases in Florida. The new findings, he said, show that 'we're not powerless in the fight against cognitive decline and Alzheimer's disease.' Isaacson, who formerly directed the Alzheimer's Prevention Clinic at NewYork-Presbyterian/Weill Cornell Medical Center, was not involved with the new research. This isn't the only study to link lifestyle to a delay in dementia. Other research presented at the Alzheimer's Association conference Monday found that regular walking can protect the brains of people with a genetic risk for Alzheimer's. The beauty of lifestyle interventions now proven to help keep cognition sharp is that they can be applied universally, said Rachel Wu, an associate professor of psychology who researches cognition in older adults at the University of California, Riverside. 'There's no downside, no side effects to doing this stuff, except just the time it takes,' Wu said. POINTER trial researchers also took blood samples and scanned participants' brains, looking for amyloid and tau, proteins associated with Alzheimer's disease that form plaques and tangles in the brain. Those samples will be included in a future analysis of study participants, said Heather Snyder, a POINTER researcher and senior vice president of medical and scientific relations at the Alzheimer's Association. 'If you have this biology, do you see a better response? Less response?' she said. 'That's the kind of meaningful question we're going to be able to ask with this data.' Additional findings are expected within the year, Snyder said. Jones is eager to see those results when they're available. 'I don't know what they saw in my brain, but I know I'm a different person,' Jones said. She's lost 30 pounds and is no longer considered prediabetic or a candidate for statins to reduce her cholesterol. 'I'm going to keep moving, eating right, socializing, monitoring my comorbidities,' she said. 'I'm going to take care of myself.' This article was originally published on Solve the daily Crossword